Firebrick Pharma Limited is an Australian pharmaceutical company focused on the development and commercialization of innovative health products, primarily in the field of infection management. Its flagship product, Nasodine Nasal Spray, utilizes povidone-iodine (PVP-I) as a broad-spectrum antiviral agent, targeting the treatment and prevention of respiratory viral infections such as the common cold. Firebrick Pharma is advancing additional formulations and brand extensions within the Nasodine line to address a broader range of applications. The company operates within the healthcare sector, specifically under the general drug manufacturing industry category, positioning itself as a defensive stock type. Firebrick Pharma holds particular significance in the Australian healthcare market by targeting unmet needs in infectious disease prevention and therapy. With commercialization activities extending to international markets—including recent introductions of Nasodine in the United States, Singapore, Fiji, and pending launch plans in the Philippines—the company reflects a strategy oriented toward global reach. Firebrick Pharma’s work is underpinned by clinical development partnerships and licensing agreements, reinforcing its role as a clinical-stage innovator in the pharmaceutical landscape.